Full Press Release Details
Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023.
IMMP
Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023
Key Takeaway: Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023
Price reaction · baseline $1.83 (2023-03-21 close) · hit after-hours · clean, no other IMMP news in the window
day 0 close
-0.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)